Accessibility Menu
Processa Pharmaceuticals logo

Processa Pharmaceuticals(NASDAQ) PCSA

Current Price$2.61
Market Cap$7.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-52%
1 Month+42%
Processa Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 2.872026-07-23
Processa Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+28.12%USD 2.242026-07-16
1 month+42.08%USD 2.022026-06-23
3 month-3.69%USD 2.982026-04-24
Year to date-0.35%USD 2.882025-12-31
1 year-52.27%USD 6.012025-07-23
3 year-98.5%USD 191.502023-07-24
5 year-99.92%USD 3,500.002021-07-23
Since inception-100%USD 102,900.092017-10-09

Processa Pharmaceuticals Financials at a Glance

Market Cap

$7.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$14.11M

EPS (TTM)

-$10.72

P/E Ratio

-0.27

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$2.61

Volume

337

Open

$2.85

Previous Close

$2.87

Daily Range

$2.61 - $2.85

52-Week Range

$1.67 - $14.24

Estimated Earnings Date

Aug 6, 2026

PCSA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Processa Pharmaceuticals

Processa develops new medicines for people with serious diseases and few treatment options. Its main focus is on cancer and digestive disorders. The company aims to improve existing drugs to make them safer and more effective.

Pipeline Parade: What Processa Makes

  • NGC-Cap (PCS6422 + capecitabine): Combination therapy for advanced breast cancer; in Phase 2 trials. (0% revenue, no commercial sales)
  • NGC-Iri (PCS11T): Early-stage drug for several solid tumors, including lung and pancreatic cancer. (0% revenue)
  • PCS12852: Oral treatment for stomach and bowel disorders like gastroparesis and constipation. (0% revenue)
  • PCS499: Tablet for rare kidney diseases, such as FSGS and IgA nephropathy. (0% revenue)
  • Digital Asset Holdings: Holds $1.4 million in CHZ tokens as part of treasury strategy. (0% revenue)

Growth Spurts: How Processa Has Evolved

  • Launched Phase 2 trial for NGC-Cap in breast cancer in 2025; first 20 patients enrolled.
  • Advanced NGC-Iri to preclinical development for multiple cancer types in 2025.
  • Completed Phase 2A trial for PCS12852 in digestive disorders; seeking partners since 2025.
  • Started digital asset treasury strategy in 2025, acquiring CHZ tokens for diversification.
  • Raised $16.6 million in equity and warrant sales in 2025 to fund operations.

What Makes Processa Stand Out

Processa focuses on improving well-known cancer drugs to lower risks and speed up development. It uses regulatory science to design efficient clinical trials and dosing plans. The company also diversifies its capital with digital assets for added financial flexibility.

Five Things You Need to Know

  • No revenue reported for 2025 or 2024; all products in development.
  • Operating loss was $14.0 million in 2025, up 16.1% from 2024.
  • Research and development expenses reached $7.8 million in 2025, up 7.4% year-over-year.
  • Cash and cash equivalents were $5.5 million as of December 31, 2025.
  • Company must raise more capital by Q2 2026 to continue operations.

Bottom Line

Processa is a small biotech focused on safer, improved cancer and digestive disease drugs. Its future depends on successful trials and securing new funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

12

CEO

George K. Ng

Website

www.processapharmaceuticals.com

Headquarters

Vero Beach, FL 21076, US

PCSA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-281.30%

Return on Capital

-250.81%

Return on Assets

-312.03%

Earnings Yield

-3.70%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.77M

Volume

337

Avg. Volume

62.46K

Financials (TTM)

Gross Profit

-$301.00

Operating Income

-$14.47M

EBITDA

-$14.11M

Operating Cash Flow

-$12.25M

Capital Expenditure

-$2.00

Free Cash Flow

-$12.25M

Cash & ST Invst.

$1.69M

Total Debt

$0.00

Processa Pharmaceuticals Performance Analysis

Processa Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Processa Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Processa Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -851.20128.2%
20232023-12-31USD -211.99-75.1%
20242024-12-31USD -96.82-54.3%
20252025-12-31USD -10.36-89.3%
Processa Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3016.0%
Q32025-09-3071.0%
Q42025-12-3127.6%
Q12026-03-311.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$301.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$7.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$662.02K

N/A

Employees

12

N/A

Net Income

-$3.38M

-19.1%

EBITDA

-$3.38M

-19.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.69M

-41.6%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-3.12%

N/A

Return on Invested Capital

-5.70%

N/A

Free Cash Flow

-$3.59M

-31.5%

Operating Cash Flow

-$3.59M

-31.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCTXBriaCell Therapeutics Corp.
$3.58-3.76%
CRISCuris, Inc.
$4.85+3.75%
CTXRCitius Pharmaceuticals, Inc.
$0.52-1.96%
HOTHHoth Therapeutics, Inc.
$0.81-3.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.22-0.07%
NOKNokia
$9.14-0.06%
CLFCleveland-Cliffs
$11.90+0.09%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.77+0.03%

Questions About PCSA

What is the current price of Processa Pharmaceuticals?

Processa Pharmaceuticals is trading at $2.61 per share.

What is the 52-week range for Processa Pharmaceuticals?

Over the past 52 weeks, Processa Pharmaceuticals has traded between $1.67 and $14.24.

How much debt does Processa Pharmaceuticals have?

As of the most recent reporting period, Processa Pharmaceuticals reported total debt of $0.00.

How much cash does Processa Pharmaceuticals have on hand?

Processa Pharmaceuticals reported $1.69M in cash and cash equivalents in its most recent financial results.

What is Processa Pharmaceuticals’s dividend yield?

Processa Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services